Rising Geriatric Population To Drive The Market Growth: Critical Driver Shaping the Global Dry Age Related Macular Degeneration (AMD) Market in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Dry Age Related Macular Degeneration (AMD) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market valuation for dry age-related macular degeneration (AMD) has experienced considerable expansion over the past few years, projected to advance from $4.49 billion in 2024 to reach $4.89 billion the subsequent year, reflecting an 8.8% compound annual growth rate. This historical upward trajectory is fueled by several key elements: an expanding elderly demographic, a higher incidence of long-term illnesses, heightened consciousness regarding ocular well-being, an escalating number of research studies concentrated on dry AMD, and a continuously increasing preference for treatment modalities that are less invasive.

Dry Age Related Macular Degeneration (AMD) Market Size Forecast: What's the Projected Valuation by 2029?
Anticipated to experience robust expansion ahead, the market concerned with dry age-related macular degeneration (AMD) is projected to reach a valuation of $6.8 billion by the year 2029, reflecting a compound annual growth rate (CAGR) of 8.6% throughout the forecast timeframe, a surge fueled by the introduction of innovative treatment modalities, escalating global healthcare spending, greater implementation of laser photocoagulation procedures, progress made in genetic studies, and an intensifying concentration on tailoring medical care to the individual, while key developments set to influence this period involve improvements in diagnostic apparatus, increased acceptance of remote eye care services, deployment of sophisticated treatment methods, and the successful gaining of regulatory clearances alongside the introduction of new medical products.

View the full report here:
https://www.thebusinessresearchcompany.com/report/dry-age-related-macular-degeneration-amd-global-market-report

What Are the Drivers Transforming the Dry Age Related Macular Degeneration (AMD) Market?
The anticipated expansion of the market for dry age-related macular degeneration (AMD) is projected to be fueled primarily by the continually increasing number of elderly individuals, a demographic generally encompassing those aged 65 and above. Multiple factors contribute to this demographic surge, including enhanced life spans, superior handling of persistent health issues, progress in medical innovations, and better provisions for elderly care. Dry AMD solutions offer the older demographic crucial therapeutic strategies and administrative approaches focused on curbing the advancement of the disorder, maintaining sight, and ultimately elevating the living standards for seniors afflicted by it. To illustrate this trend, data released in June 2024 by the US-based National Council on Aging indicated that the population aged 65 and older reached around 57.8 million in 2022, constituting 17.3% of the total US populace, a rise from the 16.9% recorded the preceding year. Consequently, the escalating size of the older adult segment is set to be a major impetus behind the growth trajectory of the dry AMD market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21176&type=smp

What Long-Term Trends Will Define the Future of the Dry Age Related Macular Degeneration (AMD) Market?
Key players within the dry age-related macular degeneration (AMD) sphere are concentrating their efforts on innovating novel, sophisticated methodologies and interventions, like light transmission apparatuses, aiming to engage retinal cells with the goal of potentially mitigating the advance of the ailment. Such light delivery apparatuses encompass technologies engineered to convey light for therapeutic purposes, specifically in clinical interventions. As an illustration, in the initial month of 2024, the American medical device firm LumiThera Inc. introduced photobiomodulation (PBM) as a treatment approach for dry age-related macular degeneration (AMD) utilizing its Valeda Light Delivery System; remarkably, this represents the inaugural FDA-cleared therapy intended to combat vision impairment in individuals afflicted by dry AMD, a disorder presently characterized by a scarcity of viable therapeutic paths. To amass enduring information concerning the results observed in individuals receiving Valeda system treatments, LumiThera commenced the EUROLIGHT registry investigation. The Valeda device employs a technique of light transmission incorporating multiple wavelengths, specifically utilizing three distinct wavelengths (590 nm, 660 nm, and 850 nm), and this gentle, non-invasive procedure can be administered whether the patient's eyelids are open or closed, usually necessitating a course of nine treatments spread across three to four weeks.

Which Segments in the Dry Age Related Macular Degeneration (AMD) Market Offer the Most Profit Potential?
The dry age related macular degeneration (amd)market covered in this report is segmented -

1) By Stages: Early Age-Related Macular Degeneration; Intermediate Age-Related Macular Degeneration; Late Age-Related Macular Degeneration
2) By Age Group: Above 75 Years; Above 60 Years; Above 40 Years
3) By Route Of Administration: Oral; Injectables
4) By End Users: Hospitals And Clinics; Diagnostic Centers; Academic And Research Institutes

Subsegments:
1) By Early Age-Related Macular Degeneration: Drusen Accumulation; Retinal Pigment Epithelium Changes
2) By Intermediate Age-Related Macular Degeneration: Larger Drusen Deposits; Increased Pigmentary Abnormalities
3) By Late Age-Related Macular Degeneration: Geographic Atrophy; Central Vision Loss

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21176&type=smp

Which Firms Dominate the Dry Age Related Macular Degeneration (AMD) Market by Market Share and Revenue in 2025?
Major companies operating in the dry age related macular degeneration (AMD) market are F Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Amgen Inc., Biogen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Lupin Ltd., Santen Pharmaceuticals Inc., Biocon Ltd., Alimera Sciences Inc., Apellis Pharmaceuticals Inc., Belite Bio Inc., Axol Bioscience Ltd., Alkeus Pharmaceuticals Inc., Kubota Holdings Co., Ribomic Inc., Eyestem Research Pvt. Ltd., LumiThera Inc., Adverum Biotechnologies Inc.

Which Regions Offer the Highest Growth Potential in the Dry Age Related Macular Degeneration (AMD) Market?
North America was the largest region in the dry age-related macular degeneration (AMD) market in 2024. The regions covered in the dry age related macular degeneration (AMD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21176

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.